| Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium P Grivas, AR Khaki, TM Wise-Draper, B French, C Hennessy, CY Hsu, ... Annals of oncology 32 (6), 787-800, 2021 | 287 | 2021 |
| Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ... JAMA oncology 7 (8), 1167-1175, 2021 | 169 | 2021 |
| CTGF is a therapeutic target for metastatic melanoma EC Finger, CF Cheng, TR Williams, EB Rankin, B Bedogni, L Tachiki, ... Oncogene 33 (9), 1093-1100, 2014 | 89 | 2014 |
| A biological global positioning system: considerations for tracking stem cell behaviors in the whole body SC Li, LML Tachiki, J Luo, BA Dethlefs, Z Chen, WG Loudon Stem Cell Reviews and Reports 6, 317-333, 2010 | 78 | 2010 |
| Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor SC Li, LML Tachiki, MH Kabeer, BA Dethlefs, MJ Anthony, WG Loudon Cancer cell international 14, 1-16, 2014 | 47 | 2014 |
| Racial disparities in COVID-19 outcomes among black and white patients with cancer J Fu, SA Reid, B French, C Hennessy, C Hwang, NT Gatson, N Duma, ... JAMA network open 5 (3), e224304-e224304, 2022 | 46 | 2022 |
| Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19 AL Schmidt, MD Tucker, Z Bakouny, C Labaki, CY Hsu, Y Shyr, ... JAMA network open 4 (11), e2134330-e2134330, 2021 | 38 | 2021 |
| Interplay of immunosuppression and immunotherapy among patients with cancer and COVID-19 Z Bakouny, C Labaki, P Grover, J Awosika, S Gulati, CY Hsu, ... JAMA oncology 9 (1), 128-134, 2023 | 29 | 2023 |
| Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium A Elkrief, C Hennessy, NM Kuderer, SM Rubinstein, E Wulff-Burchfield, ... The Lancet Healthy Longevity 3 (3), e143-e152, 2022 | 19 | 2022 |
| A systematic framework to rapidly obtain data on patients with cancer and COVID-19: CCC19 governance, protocol, and quality assurance M Abidi, DM Aboulafia, MK Accordino, JD Acoba, MS Ahluwalia, ... Cancer cell 38 (6), 761-766, 2020 | 18 | 2020 |
| Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study S Bhatia, P Nghiem, SP Veeranki, A Vanegas, K Lachance, L Tachiki, ... Journal for immunotherapy of cancer 10 (8), 2022 | 14 | 2022 |
| Assessment of regional variability in COVID-19 outcomes among patients with cancer in the United States JE Hawley, T Sun, DD Chism, N Duma, JC Fu, NTN Gatson, S Mishra, ... JAMA network open 5 (1), e2142046-e2142046, 2022 | 9 | 2022 |
| Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma GK In, A Nallagangula, JS Choi, L Tachiki, MJ Blackburn, S Capone, ... Journal for immunotherapy of cancer 10 (5), 2022 | 8 | 2022 |
| Demographics, outcomes, and risk factors for patients with sarcoma and COVID-19: a CCC19-Registry based retrospective cohort study MJ Wagner, C Hennessy, A Beeghly, B French, DP Shah, S Croessmann, ... Cancers 14 (17), 4334, 2022 | 4 | 2022 |
| Outcomes of patients with COVID-19 from a specialized cancer care emergency room SS Nath, NU Yadav, A Derkach, R Perez-Johnston, L Tachiki, K Maguire, ... Cancer investigation 40 (1), 17-25, 2022 | 3 | 2022 |
| Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma LML Tachiki, DS Hippe, K Williams Silva, ET Hall, W McCamy, D Fritzsche, ... Cancer Immunology, Immunotherapy 72 (11), 3839-3850, 2023 | 2 | 2023 |
| Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma DB Johnson, MB Atkins, C Hennessy, T Wise-Draper, H Heilman, ... BMC cancer 23 (1), 265, 2023 | 2 | 2023 |
| An intratumoral STING agonist-mediated clinical response in PD-L1-refractory MCC via an unexpected mechanism of action TH Pulliam, R Bhakuni, S Jani, K Smythe, B Seaton, L Tachiki, ... Journal of Investigative Dermatology 142 (10), 2839, 2022 | 2 | 2022 |
| Extended duration of anti-PD-1 therapy, using reduced frequency dosing, in patients with advanced melanoma and Merkel cell carcinoma. LML Tachiki, K Williams Silva, DS Hippe, D Fritzsche, A Raczka, A Perdue, ... Journal of Clinical Oncology 40 (16_suppl), 2588-2588, 2022 | 2 | 2022 |
| Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis. MJ Wagner, M Ingham, C Painter, R Chugh, JC Trent, V Subbiah, ... Journal of Clinical Oncology 39 (15_suppl), 11523-11523, 2021 | 2 | 2021 |
